• News
  • BioTech

Targeson receives $776,800 in year 2 of SBIR grant

San Diego's Targeson Inc. announced it has received the Notice of Award for year 2 of the company’s 2R44 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

This project, entitled “Selectin Targeted Ultrasound Contrast Agents for Detection of Acute Coronary Syndrome,” will explore the use of Targeson’s targeted microspheres as a diagnostic imaging test for detecting recent myocardial ischemia.

Research will be conducted in conjunction with professor Anthony DeMaria, M.D., at the University of California, San Diego.

Current methods for assessing the extent of cardiac ischemic injury in an acute setting offer limited sensitivity and specificity, which leads to both under- and over-treatment of patients with suspected acute coronary syndrome.

The aim of this grant will be to investigate a novel microsphere contrast agent targeted to a molecular marker of recent ischemia, enabling visualization of recent myocardial ischemia using echocardiography (cardiac ultrasound).

Targeson has identified a novel targeting agent and developed a biocompatible coupling chemistry suitable for eventual translation to human use. Target-binding activity and efficacy will be studied in animal models to characterize and validate the imaging agent. Initial safety studies will be performed in animal models to enable a future investigational new drug submission.

User Response
0 UserComments

Targeson Inc.

Company Website

3550 General Atomics Ct. MS, 02-606
San Diego, CA 92121

Targeson Inc. Executive(s):

Joshua Rychak

  • Co-Founder